GAMMA Investing LLC Boosts Holdings in Repligen Corporation (NASDAQ:RGEN)

GAMMA Investing LLC increased its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 40.1% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 958 shares of the biotechnology company’s stock after buying an additional 274 shares during the period. GAMMA Investing LLC’s holdings in Repligen were worth $122,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Signaturefd LLC increased its holdings in Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after buying an additional 124 shares during the last quarter. Sava Infond d.o.o. purchased a new stake in Repligen during the fourth quarter worth about $29,000. Raiffeisen Bank International AG purchased a new position in shares of Repligen in the fourth quarter worth about $29,000. Itau Unibanco Holding S.A. purchased a new position in shares of Repligen in the fourth quarter worth about $40,000. Finally, Pilgrim Partners Asia Pte Ltd purchased a new position in shares of Repligen in the fourth quarter worth about $55,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Trading Up 0.3%

Shares of Repligen stock opened at $127.36 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.79 and a quick ratio of 5.79. Repligen Corporation has a 1 year low of $102.97 and a 1 year high of $182.52. The firm has a market cap of $7.16 billion, a PE ratio of -283.02, a PEG ratio of 3.65 and a beta of 1.11. The company has a 50 day simple moving average of $126.70 and a two-hundred day simple moving average of $139.91.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping analysts’ consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The business had revenue of $169.17 million during the quarter, compared to analysts’ expectations of $163.65 million. During the same quarter in the previous year, the company earned $0.28 EPS. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. Analysts expect that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Canaccord Genuity Group reduced their target price on shares of Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a research note on Wednesday, April 16th. Wolfe Research upgraded shares of Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 target price for the company in a research note on Tuesday, April 29th. JPMorgan Chase & Co. reduced their target price on shares of Repligen from $200.00 to $190.00 and set an “overweight” rating for the company in a research note on Tuesday, April 29th. Wall Street Zen downgraded shares of Repligen from a “buy” rating to a “hold” rating in a research note on Sunday, June 29th. Finally, Evercore ISI assumed coverage on shares of Repligen in a research note on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 target price for the company. Five investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $172.83.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.